DOCSLIB.ORG

Nhs Southampton City/Nhs Hampshire/Southampton

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nhs Southampton City/Nhs Hampshire/Southampton SOUTHAMPTON JOINT FORMULARY CUMULATIVE UPDATE This document is a cumulative list summarising changes to the Southampton Joint Formulary. To check the current status of a medicine please refer to www.southamptonformulary.nhs.uk Date Drug and formulation Colour BNF Comments Action status section 16/03/21 Pertuzumab/ Red 8.1.5 From 10/02/2021 NHS England and Add trastuzumab Improvement will commission the subcutaneous injection new combined pertuzumab and [Phesgo] trastuzumab subcutaneous injection, brand name PHESGO®, for all existing pertuzumab and trastuzumab indications as an alternative to IV pertuzumab and trastuzumab (NICE TA424, NICE TA509, NICE TA569) 16/03/21 Pembrolizumab injection Black 8.1.5 Funding from the Cancer Drugs Fund Remove [Keytruva] for 1st line use in urothelial cancer has been ceased from 17th Feb 2021 following publication of NICE terminated guidance (NICE TA674)- NICE TA522 has been replaced. 16/03/21 Pembrolizumab injection Red 8.1.5 NICE TA683: Pembrolizumab with Amend [Keytruva] pemetrexed and platinum chemotherapy is recommended as an option for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)‑ positive or anaplastic lymphoma kinase (ALK)‑positive mutations 16/03/21 Erenumab prefilled Red 4.7.4.2 NICE TA682: Erenumab for Add 140mg injection preventing migraine [Amiovig®] only if: they have 4 or more migraine days a month at least 3 preventive drug treatments have failed the 140 mg dose of erenumab is used and the company provides it according to the commercial arrangement. (both chronic and episodic) 16/03/21 Lenalidomide [Revlimid] Red 8.2.4 NICE TA680 Lenalidomide is Amend capsules recommended as maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults, only if: the dosage schedule is 10 mg per day on days 1 to 21 of a 28‑day cycle and the company provides lenalidomide according to the commercial arrangement. 16/03/21 Baricitinib tablets Red 13.5.3 NICE TA681:Baricitinib is Amend [Olumiant®] recommended as an option for treating moderate to severe atopic dermatitis in adults, only if: the disease has not responded to at least 1 systemic immunosuppressant, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil, or these are not suitable, and the company provides it according to the commercial arrangement. 16/03/21 Filgotinib tablets Red 10.1.3 NICE TA676:Filgotinib, with Add [Jyseleca®] methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with 2 or more conventional disease-modifying antirheumatic drugs (DMARDs), only if: disease is moderate or severe (a disease activity score [DAS28] of 3.2 or more) and the company provides filgotinib according to the commercial arrangement. 16/03/21 Niraparib capsules Red 8.1.5 NICE TA673: Niraparib for Amend [Zejula] maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Use within cancer drug fund 16/03/21 Brolucizumab [Beovu] Red 11.8.2 NICE TA672: Brolucizumab is Add prefilled injection recommended as an option for treating wet age-related macular degeneration in adults, only if, in the eye to be treated: •the best-corrected visual acuity is between 6/12 and 6/96 •there is no permanent structural damage to the central fovea •the lesion size is less than or equal to 12 disc areas in greatest linear dimension and •there is recent presumed disease progression (for example, blood vessel growth, as shown by fluorescein angiography, or recent visual acuity changes). It is recommended only if the company provides brolucizumab according to the commercial arrangement. 16/03/21 Mepolizumab [Nucala] Red 3.4.2 NICE TA431 updated and replaced Add injection/pre-filled by NICE TA671 (Mepolizumab for syringes treating severe eosinophilic asthma) 16/03/21 Omalizumab injection Black 3.4.2 NICE TA678 Omalizumab for treating NFD [Xolair®] chronic rhinosinusitis with nasal polyps (terminated appraisal) The company has confirmed that it does not intend to make a submission for the appraisal because the technology will not be launched in the UK for treating this indication. 16/03/21 Vernakalant infusion Black 2.3.2 NICE TA675: Vernakalant for the NFD [Brinavess®] rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal) The company has confirmed that it does not intend to make a submission because it considers there is insufficient evidence. 16/03/21 Desmopressin Amber 6.5.2 Urologist recommendation only. Amend oral lyophilisate tabs (I) Initiated by UHS, along with initial [Noqdirna] sodium monitoring. Then can be continued by primary care. SCG not required as per DPC discussion Feb 2021 16/03/21 Subcutaneous infliximab Red 10.1.3 Alternative route to IV. For use in Add prefilled syringes/pens 1.5.3 rheumatology and gastroenterology [Remsima®] indications. Funding approved 16/02/21 Estradiol/ Green 6.4.1.1 HRT option for women with intact Add Dydrogesterone. uterus [Femoston/ Femoston Conti tablet] 16/02/21 Droperidol injection Red 4.6 Prevention and treatment of PONV in Add paediatrics (second-line to ondansetron and dexamethasone. Restricted to anaesthetist use only. Guideline in development 16/02/21 Nefopam tablets Red 4.7.1 Analgesic for post-operative acute Add pain when other analgesics (paracetamol, NSAIDS and opioids) are found to be ineffective, not tolerated or contraindicated. Pain team recommendation only. Not for use in chronic pain 16/02/21 Semaglutide solution for Red 6.1.2.3 Type 2 diabetes mellitus in children Amend injection [Ozempic] ≥10y, not adequately controlled with diet, exercise, and metformin alone (or where metformin is contraindicated or not tolerated). Severe obesity in children ≥10y with comorbidities, where a) Weight management is not adequately controlled with diet, exercise, and metformin (or where metformin is contraindicated or not tolerated), or b) Exceptional circumstances prevent adherence to the above measures (e.g., severely autism, severe learning disabilities, immobility). 16/02/21 Phenol Swabs Red 13.11.5 Used for the treatment/ ablation of Add in-growing toe nails. 16/02/21 Nortriptyline Black 4.3.1 For treatment of post-stroke Remain tablets/capsules depression in updated Southern NFD Health guidelines. Currently not supported for this indication in DPC area – remains NFD 16/02/21 Dapagliflozin tablets Amber 6.1.2.3 NICE TA679: Dapagliflozin for Amend (I) treatment of heart failure with reduced ejection fraction in patients with OR without diabetes GPs may prescribe following specialist recommendation/SCG (not yet completed) 16/02/21 Semaglutide tabs Green 6.1.2.3 Second line to injectable GLP1-RAs Add [Rybelsus] for management of T2DM GPs should seek specialist advice if seeking to switch patients from injectable to oral. 16/02/21 Hypertonic glucose 50% NFD 6.1.4 For use in prolotherapy. Add as injection NFD Individual patients may be considered via IFR application. 16/02/21 Brigatinib tablet Red 8.1.5 NICE TA670: Brigatinib for Amend [Alunbrig®] anaplastic lymphoma kinase (ALK)- positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor (may be offered as an alternative to alectinib or crizotinib) 16/02/21 Encorafenib capsules Red 8.1.5 NICE Amend [Braftovi®] TA668: Encorafenib plus cetuximab f or previously treated BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment 16/02/21 Atezolizumab infusion Red 8.1.5 NICE Amend [Tecentriq®] TA666: Atezolizumab (Tecentriq) with bevacizumab (Avastin or licensed biosimilar products) for treating advanced or unresectable hepatocellular carcinoma in adults who have not had previous systemic treatment, only if: they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 16/02/21 Caplacizumab infusion/ Red 9.1 NICE TA667: Caplacizumab with Add subcutaneous injection plasma exchange and [Calblivi®] immunosuppression is recommended, within its marketing authorisation, as an option for treating an acute episode of acquired thrombotic thrombocytopenic purpura (aTTP) in adults, and in young people aged 12 years and over who weigh at least 40 kg. 16/02/21 Venetoclax tablet Red 8.1.5 NICE Amend [Venclyxto®] TA663: Venetoclax plus obinutuzum ab is recommended as an option for untreated chronic lymphocytic leukaemia (CLL) in adults, only if: there is a 17p deletion or TP53 mutation, or there is no 17p deletion or TP53 mutation, and fludarabine plus cyclophosphamide and rituximab (FCR), or bendamustine plus rituximab (BR), is unsuitable Note: venetoclax plus obinutuzumab is recommended for use within the Cancer Drugs Fund as an option for untreated CLL in adults, only if: there is no 17p deletion or TP53 mutation, and FCR or BR is suitable, and conditions for managed access agreement are followed. 16/02/21 Liraglutide Red 6.1.2.3 NICE TA664: Liraglutide (Saxenda) Amend subcutaneous injection for managing overweight and [only Saxenda®] obesity alongside a reduced-calorie diet and increased physical activity in adults only if (all criteria must be met): BMI of at least 35kg/m2 have non-diabetic hyperglycaemia high risk of cardiovascular disease prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service 16/02/21
Load more

Recommended publications
  • WO 2018/223101 Al 06 December 2018 (06.12.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/223101 Al 06 December 2018 (06.12.2018) W !P O PCT (51) International Patent Classification: (71) Applicant: JUNO THERAPEUTICS, INC. [US/US]; 400 A 61K 35/1 7 (20 15.0 1) A 61P 35/00 (2006 .0 1) Dexter Ave. N., Suite 1200, Seattle, WA 98109 (US). (21) International Application Number: (72) Inventor: ALBERTSON, Tina; 400 Dexter Ave. N., Suite PCT/US2018/035755 1200, Seattle, WA 98109 (US). (22) International Filing Date: (74) Agent: AHN, Sejin et al; Morrison & Foerster LLP, 1253 1 0 1 June 2018 (01 .06.2018) High Bluff Drive, Suite 100, San Diego, CA 92130-2040 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, (30) Priority Data: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/5 14,774 02 June 2017 (02.06.2017) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/5 15,530 05 June 2017 (05.06.2017) US DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/521,366 16 June 2017 (16.06.2017) u s HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/527,000 29 June 2017 (29.06.2017) u s KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 62/549,938 24 August 2017 (24.08.2017) u s MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/580,425 0 1 November 2017 (01 .11.2017) u s OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/593,871 0 1 December 2017 (01 .12.2017) u s SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 62/596,764 08 December 2017 (08.12.2017) u s TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: a Focus on the Present and an Outlook on the Future
    biomolecules Review JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future 1, 2, , 3 1,4 Jacopo Angelini y , Rossella Talotta * y , Rossana Roncato , Giulia Fornasier , Giorgia Barbiero 1, Lisa Dal Cin 1, Serena Brancati 1 and Francesco Scaglione 5 1 Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan, 20133 Milan, Italy; [email protected] (J.A.); [email protected] (G.F.); [email protected] (G.B.); [email protected] (L.D.C.); [email protected] (S.B.) 2 Department of Clinical and Experimental Medicine, Rheumatology Unit, AOU “Gaetano Martino”, University of Messina, 98100 Messina, Italy 3 Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Pordenone, 33081 Aviano, Italy; [email protected] 4 Pharmacy Unit, IRCCS-Burlo Garofolo di Trieste, 34137 Trieste, Italy 5 Head of Clinical Pharmacology and Toxicology Unit, Grande Ospedale Metropolitano Niguarda, Department of Oncology and Onco-Hematology, Director of Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan, 20162 Milan, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-090-2111; Fax: +39-090-293-5162 Co-first authors. y Received: 16 May 2020; Accepted: 1 July 2020; Published: 5 July 2020 Abstract: Janus kinase inhibitors (JAKi) belong to a new class of oral targeted disease-modifying drugs which have recently revolutionized the therapeutic panorama of rheumatoid arthritis (RA) and other immune-mediated diseases, placing alongside or even replacing conventional and biological drugs.
    [Show full text]
  • Study Protocol
    (rJ GI LEAi) Galapagos CLINICAL STUDY PROTOCOL Study Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn’s Disease (SBCD) Sponsor: Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404, USA IND Number: 129646 EudraCT Number: 2016-003179-23 Clinical Trials.gov NCT03046056 Identifier: Indication: Small Bowel Crohn’s Disease Protocol ID: GS-US-419-4015 Contact Information: The medical monitor name and contact information will be provided on the Key Study Team Contact List. Protocol Original: 12 September 2016 Version/Date: Amendment 1: 16 December 2016 Amendment 2: 26 June 2017 Amendment 3: 04 February 2020 CONFIDENTIALITY STATEMENT The information contained in this document, particularly unpublished data, is the property or under control of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Institutional Review Board or Independent Ethics Committee. The information is only to be used by you in connection with authorized clinical studies of the investigational drug described in the protocol. You will not disclose any of the information to others without written authorization from Gilead Sciences, Inc., except to the extent necessary to obtain informed consent from those persons to whom the drug may be administered. Filgotinib Protocol GS-US-419-4015 Final Gilead Sciences, lnc. Amendment3 TABLE OF CONTENTS TABLE
    [Show full text]
  • Recommendations from York and Scarborough Medicines
    Recommendations from York and Scarborough Medicines Commissioning Committee March 2021 Drug name Indication Recommendation, rationale and place in RAG status Potential full year cost impact therapy CCG commissioned Technology Appraisals 1. TA672: Brolucizumab for Brolucizumab is recommended as an option for treating wet Listed as RED Discussed and approved at Feb 2021 MCC meeting. treating wet age-related age-related macular degeneration in adults, only if, in the eye drug macular degeneration to be treated: the best-corrected visual acuity is between 6/12 and Commissioning: CCG, 6/96 tariff excluded there is no permanent structural damage to the central fovea the lesion size is less than or equal to 12 disc areas in greatest linear dimension and there is recent presumed disease progression (for example, blood vessel growth, as shown by fluorescein angiography, or recent visual acuity changes). It is recommended only if the company provides brolucizumab according to the commercial arrangement. If patients and their clinicians consider brolucizumab to be one of a range of suitable treatments, including aflibercept and ranibizumab, choose the least expensive (taking into account administration costs and commercial arrangements). Only continue brolucizumab in people who maintain an adequate response to therapy. Criteria for stopping should include persistent deterioration in visual acuity and identification of anatomical changes in the retina that indicate inadequate response to therapy. 2. TA675: Vernakalant for NICE is unable to make a recommendation about the Not listed No cost impact to CCGs as appraisal terminated by the rapid conversion of use in the NHS of vernakalant for the rapid conversion NICE and insufficient evidence to approve use.
    [Show full text]
  • Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
    REVIEW published: 09 July 2021 doi: 10.3389/fimmu.2021.686155 Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis † † Jie Huang 1 , Xuekun Fu 1 , Xinxin Chen 1, Zheng Li 1, Yuhong Huang 1 and Chao Liang 1,2* 1 Department of Biology, Southern University of Science and Technology, Shenzhen, China, 2 Institute of Integrated Bioinfomedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China Rheumatoid arthritis (RA) is a systemic poly-articular chronic autoimmune joint disease that mainly damages the hands and feet, which affects 0.5% to 1.0% of the population worldwide. With the sustained development of disease-modifying antirheumatic drugs (DMARDs), significant success has been achieved for preventing and relieving disease activity in RA patients. Unfortunately, some patients still show limited response to DMARDs, which puts forward new requirements for special targets and novel therapies. Understanding the pathogenetic roles of the various molecules in RA could facilitate discovery of potential therapeutic targets and approaches. In this review, both Edited by: existing and emerging targets, including the proteins, small molecular metabolites, and Trine N. Jorgensen, epigenetic regulators related to RA, are discussed, with a focus on the mechanisms that Case Western Reserve University, result in inflammation and the development of new drugs for blocking the various United States modulators in RA. Reviewed by: Åsa Andersson, Keywords: rheumatoid arthritis, targets, proteins, small molecular metabolites, epigenetic regulators Halmstad University, Sweden Abdurrahman Tufan, Gazi University, Turkey *Correspondence: INTRODUCTION Chao Liang [email protected] Rheumatoid arthritis (RA) is classified as a systemic poly-articular chronic autoimmune joint † disease that primarily affects hands and feet.
    [Show full text]
  • Jyseleca, INN-Filgotinib
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Jyseleca 100 mg film-coated tablets Jyseleca 200 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Jyseleca 100 mg film-coated tablets Each film-coated tablet contains filgotinib maleate equivalent to 100 mg of filgotinib. Excipient with known effect Each 100 mg film-coated tablet contains 76 mg of lactose (as monohydrate). Jyseleca 200 mg film-coated tablets Each film-coated tablet contains filgotinib maleate equivalent to 200 mg of filgotinib. Excipient with known effect Each 200 mg film-coated tablet contains 152 mg of lactose (as monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Jyseleca 100 mg film-coated tablets Beige 12 × 7 mm, capsule-shaped, film-coated tablet debossed with “GSI” on one side and “100” on the other side. Jyseleca 200 mg film-coated tablets Beige 17 × 8 mm, capsule-shaped, film-coated tablet debossed with “GSI” on one side and “200” on the other side. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Jyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Jyseleca may be used as monotherapy or in combination with methotrexate (MTX).
    [Show full text]
  • Study Protocol
    ~ GILEAU CLINICAL STUDY PROTOCOL Study Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-9876 in Subjects with Active Rheumatoid Althritis on Background Therapy with Methotrexate Sponsor: Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 INDNumber: IND 123903 EudraCT Number: 2016-001496-75 Clinical Trials.gov Identifier: TBD Indication: Rheumatoid Arthritis Protocol ID: GS-US-379-1582 Gilead Clinical Name: TomDoan Program Manager: Telephone: PPD Gilead Medical Name: Franziska Matzkies Monitor: Telephone: PPD Fax: PPD Mobile: PPD Protocol Version/Date: Original: 08 April 2016 Amendment 1: 27 Jlme 2016 CONFIDENTIALITY STATEMENT The infonnation contained in this document, pruticularly unpublished data, is the prope1ty or under control of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Institutional Review Board or Independent Ethics Committee. The infmmation is only to be used by you in connection with authorized clinical studies of the investigational dmg described in the protocol. You will not disclose any of the infmmation to others without written authorization from Gilead Sciences, Inc., except to the extent necessa1y to obtain inf01med consent from those persons to whom the dmg may be administered. GS-9876 Protocol GS-US-379-1582 Gilead Sciences, Inc. Amendment 1 TABLE OF CONTENTS TABLE OF CONTENTS ..............................................................................................................................................2
    [Show full text]
  • CHMP Agenda of the 19-22 April 2021 Meeting
    28 July 2021 EMA/CHMP/220334/2021 Corr.11 Human Medicines Division Committee for medicinal products for human use (CHMP) Agenda for the meeting on 19-22 April 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes 19 April 2021, 09:00 – 19:30, virtual meeting/ room 1C 20 April 2021, 08:30 – 19:30, virtual meeting/ room 1C 21 April 2021, 08:30 – 19:30, virtual meeting/ room 1D 22 April 2021, 08:30 – 19:00, virtual meeting/ room 1C Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). 1 Correction in section 8.1.1 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021.
    [Show full text]
  • Statistical Analysis Plan
    (r) GILEAU STATISTICAL ANALYSIS PLAN Study Title: A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Name of Test Drug: Filgotinib Study Number: GS-US-417-0301 Protocol Version (Date): Amendment 1: 05 July 2016 Analysis Type: Week 24 Analysis and Final Analysis Analysis Plan Version: Version 1.0 Analysis Plan Date: 05 February 2019 Analysis Plan Author(s): -PPD CONFIDENTIAL AND PROPRIETARY INFORMATION Filgotinib GS-US-417-0301 Statistical Analysis Plan – Week 24 Analysis and Final Analysis Version 1.0 TABLE OF CONTENTS TABLE OF CONTENTS ..............................................................................................................................................2 LIST OF IN-TEXT TABLES........................................................................................................................................5 LIST OF IN-TEXT FIGURES ......................................................................................................................................5 LIST OF ABBREVIATIONS........................................................................................................................................6 PHARMACOKINETIC ABBREVIATIONS................................................................................................................9
    [Show full text]
  • The LEONARDO Study Final Report
    UtiLization pattErns, access to healthcare facilities and ecONomic Assessment of JAKi dRugs useD in rheumatOid arthritis patients in Tuscany: the LEONARDO study Final Report 1 Authors Marco Tuccori Giuseppe Turchetti Rosa Gini Valentina Lorenzoni Ersilia Lucenteforte Sabrina Giometto Claudia Bartolini Olga Paoletti Irma Convertino Sara Ferraro Emiliano Cappello Giulia Valdiserra Corrado Blandizzi 2 Table of contents 1 Background ................................................................................................................................................... 4 1.1 Tofacitinib .............................................................................................................................................. 6 1.2 Baricitinib ............................................................................................................................................. 11 1.3 Other JAK inhibitors ............................................................................................................................. 16 2 Objective ..................................................................................................................................................... 20 3 Research questions ..................................................................................................................................... 20 4 Methods ...................................................................................................................................................... 21 4.1 Study design
    [Show full text]
  • Efficacy and Safety of Filgotinib, a Selective Janus Kinase 1 Inhibitor
    UCSF UC San Francisco Previously Published Works Title Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Permalink https://escholarship.org/uc/item/98d1m6ss Journal Lancet (London, England), 392(10162) ISSN 0140-6736 Authors van der Heijde, Désirée Baraliakos, Xenofon Gensler, Lianne S et al. Publication Date 2018-12-01 DOI 10.1016/s0140-6736(18)32463-2 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Articles Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial Désirée van der Heijde, Xenofon Baraliakos, Lianne S Gensler, Walter P Maksymowych, Vira Tseluyko, Oleg Nadashkevich, Walid Abi-Saab, Chantal Tasset, Luc Meuleners, Robin Besuyen, Thijs Hendrikx, Neelufar Mozaffarian, Ke Liu, Joy M Greer, Atul Deodhar, Robert Landewé Summary Lancet 2018; 392: 2378–87 Background At present, biological disease-modifying anti-rheumatic drugs (DMARDs) are the only treatment Published Online recommended for patients with ankylosing spondylitis who have not responded to first-line treatment with non- October 22, 2018 steroidal anti-inflammatory drugs (NSAIDs). The TORTUGA trial investigated the efficacy and safety of filgotinib, an http://dx.doi.org/10.1016/ oral selective Janus kinase 1 (JAK1) inhibitor, for the treatment of patients with active ankylosing spondylitis. S0140-6736(18)32463-2 See Comment page 2328 Methods In this completed, randomised, double-blind, placebo-controlled, phase 2 trial, we enrolled adult patients Department of Rheumatology, Leiden University Medical from 30 sites in seven countries (Belgium, Bulgaria, Czech Republic, Estonia, Poland, Spain, and Ukraine).
    [Show full text]
  • Immunology Lecture Edinburgh
    Kinases in immunology: «A mini Review» Immunopharmacology Meeting Edinburgh 2018-10-02 Outline • Introduction to Kinases • Kinases & immunology: where are we ? • Selected examples for immuno kinases: JAK, SYK, RIPK, IRAK..... and • PI3Kδ: Leniolisib from the bench to the bedside Why are kinase attractive drug targets ? • Druggable by ATP (ITB) and/or non-ATP (OTB) inhibitors • Large knowledge-base of structures and inhibitors • Genetics, differential cytotox (synthetic lethal), host mechanisms • Non-oncological indications ? Disease Kinase K LKB1 (LoF) Peutz-Jegher Syndrome ATM (LoF) Ataxia Telangectasia I WNK1 (GoF) Gordon Hypertension Syndrome N mTOR (GoF) LoF of TSC1 and TSC2 (Tubersclerosis, Hamartomas) B-raf (GoF) Melanoma & other sporadic carcinomas A LRRK2 (GoF) Hereditary early onset Parkinson S PI3Ka (GoF) Sporadic carcinomas BTK (LoF) X-linked a-gamma-globulinaemia E Ret (GoF) Men2A, Medullary Thyroid Cancer, Chrom. rearrang. In PTC P ZAP70 (LoF) CD8 deficiency form of SCID T Jak2 (GoF) V617F in PV, ET, IMF; Transl in Leukemia Muts im AML Jak3 (LoF) SCID (X-linked), A Alk (GoF) Translocation in ALCL, IMF and NSCLC H ErbB1-4 Amplification & overex. in Carcinomas PDGFR (GoF) GIST, chrom. rearrang. in CML, CMML and HES I FGFR1 & 2 (GoF) Craniosynostosis & Crouzon/Pfeiffer thanatophoric dysp. E FGFR3 (GoF) Chrom. rearrang. & muts in leukemia, myeloma, dwarfism, bladder S VEGFR3 (LoF) Hereditary lymphedema. Host mechanisms Met (GoF) Amplification & overex. in sporadic & hereditary Ca InsR (LoF) Type II diabetes, Leprechaunism Rous
    [Show full text]